#United States #New York #Class Action #Gross Law Firm #Revance Therapeutics

Revance Therapeutics Shareholders: Important Notice

Attention shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC)! If you purchased shares during the critical period between February 29, 2024, and December 6, 2024, you may be eligible to participate in a class action lawsuit. Led by The Gross Law Firm, this action provides an opportunity for shareholders who have suffered financial losses due to misleading statements made by the company.

Understanding the Allegations

The complaint against Revance alleges several key points that underscore why shareholders should consider joining the class action:

1. Breach of Agreement: During the stated period, Revance is claimed to have been in material breach of its Distribution Agreement with Teoxane. This agreement was crucial as it granted Revance exclusive rights to market, sell, and distribute Teoxane’s line of dermal fillers.
2. Litigation Risks: As a result of these breaches, the company faced increased risk of litigation and potential damage to its reputation, both of which could significantly affect its stock market performance.
3. False Public Statements: The lawsuit alleges that the statements issued by Revance during this time were materially false and misleading, failing to disclose the ongoing legal and financial dangers associated with their agreements.
4. Impact on Stock Value: These factors contributed to a false inflation of the company's stock price, leaving shareholders at a loss when the truth came to light.

Key Dates for Shareholders

• - Class Period: February 29, 2024 - December 6, 2024
• - Deadline to Join Class Action: March 4, 2025

Shareholders are strongly encouraged to register as soon as possible to ensure they are included in the action. Early registration also provides additional benefits, such as access to portfolio monitoring software that keeps you updated on the status of the case.

Next Steps for Affected Shareholders

If you believe you may qualify for this class action, visit this link to register your information.

This registration does not incur any costs or obligations on your part. Also, being appointed as a lead plaintiff is not a prerequisite for participating in recoveries related to the action.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its dedication to protecting the rights of investors. With a focus on accountability, the firm aims to hold companies responsible for misleading their shareholders, ensuring the integrity of corporate actions in the marketplace. By participating in this class action, you will contribute to a firm effort aimed at restoring losses incurred due to untruthful practices.

Contact Information

For inquiries or additional information, shareholders are encouraged to reach out to The Gross Law Firm at:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018

Conclusion

Don’t delay! If you suffered losses as a shareholder of Revance Therapeutics, consider joining the ongoing class action. Your participation could lead to rightful recoveries for damages endured due to the company’s alleged misconduct. Take the necessary steps today to safeguard your rights as an investor.